Text Size

A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT01159808
First received: July 1, 2010
Last updated: June 21, 2012
Last verified: June 2012
History of Changes
  Purpose

The purpose of this study is to test the safety of different dose strengths of INX-08189 in healthy adults. The study will also look at how rapidly the drug breaks down in the body (pharmacokinetics or PK). The study objectives include:

  • To evaluate the safety of single ascending oral doses of INX-08189 in healthy subjects
  • To characterize the pharmacokinetic (PK) profile of single ascending oral doses of INX-08189 in healthy subjects
  • To assess the food effect on the PK of a single oral dose of INX-08189

Condition Intervention Phase
Healthy
 Drug: INX-08189
Drug: Placebo
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Official Title: A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy Subjects

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Evaluate the safety of single ascending oral doses of INX-08189 in healthy subjects [ Time Frame: periodically over 14 days ] [ Designated as safety issue: Yes ]
    Safety will be evaluated on the basis of adverse event (AE) incidence, changes in serum chemistry and hematology values, urinalysis results, and changes in vital signs and in electrocardiogram (ECG) findings.

  • Characterize the pharmacokinetic (PK) profile of single ascending oral doses of INX-08189 in healthy subjects [ Time Frame: periodically over 14 days ] [ Designated as safety issue: Yes ]
    Including a determination of maximum observed plasma concentration (Cmax), time at which the maximum plasma concentration was observed (Tmax), time at which concentrations are first measurable in the plasma (Tlag), area under the plasma concentration-time curve from time 0 to time of last measurable plasma concentration (AUC 0-last) and elimination half-life (T 1/2) after single ascending oral doses.

  • Assess the effect of a high fat meal on the PK parameters [ Time Frame: periodically over 14 days ] [ Designated as safety issue: Yes ]
    The effect of food (standard high-fat meal) on the absorption of INX-08189 will be evaluated


Enrollment: 42
Study Start Date: May 2010
Study Completion Date: October 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: INX-08189 Drug: INX-08189
3, 25 and 100 mg capsules; oral administration, single dose
Placebo Comparator: Placebo Drug: Placebo
matching placebo capsules, oral administration, single dose

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy men and post-menopausal (absence of periods for more than 2 years) surgically sterile, or non-pregnant, non-lactating women using a reliable form of contraception (see Inclusion Criteria 9)
  2. Age 18 to 65 years, inclusive
  3. Normal (no clinically significant abnormalities) laboratory tests (chemistry, hematology and urinalysis)
  4. No clinically significant abnormalities on ECG (QTcB interval must be < 450 ms)
  5. Weight ≥ 50kg and Body Mass Index (BMI) of 19 to 30, inclusive
  6. Negative urine drug screen at screening and on Study Day -1
  7. Negative serum βHCG pregnancy test at screening and on Study Day -1 (for all women)
  8. Hepatitis B surface antigen, hepatitis C antibody, and HIV antibody negative
  9. Agreement to practice a barrier method of birth control plus the use of a spermicide throughout the study period by both male and female subjects (oral contraceptives are not permitted)
  10. Able to complete all study visits
  11. Signed informed consent form (ICF)

Exclusion Criteria:

  1. Any active medical problem for which the subject is being evaluated and/or treated
  2. Calculated creatinine clearance (calculated using the IDMS traceable equation for the MDRD value) < 50 mL/min/1.73 m2
  3. Regular use of medications, prescription or non-prescription; no medication may be taken within 1 week prior to study dosing
  4. Use of alcohol within 48 hours prior to dosing (subjects must also agree to not use alcohol for 96 hours after dosing)
  5. Current lactation or breastfeeding
  6. Major surgery within 30 days prior to dosing
  7. Receipt of an investigational drug within 30 days prior to dosing
  8. Donation of blood or plasma within 30 days prior to dosing
  9. Any other problem, that in the opinion of the Investigator, will affect the safety of the subject or outcome of the study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01159808

Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Brian Boehlecke, MD, MSPH
  More Information

No publications provided

Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01159808     History of Changes
Other Study ID Numbers: AI472-001, INH-189-001
Study First Received: July 1, 2010
Last Updated: June 21, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Bristol-Myers Squibb:
Safety and Pharmacokinetics

ClinicalTrials.gov processed this record on June 18, 2013